Flagship Pioneering

#FlagshipFounded Mirai Bio announces a partnership with Thermo Fisher Scientific to accelerate the development of genetic medicines. This collaboration expands our ongoing collaboration with Thermo Fisher and reflects our shared vision for accelerating the development of enabling technologies to create breakthrough therapies: https://bit.ly/4k2ohCi 

Meet Erica Imoisi, Flagship Administrative Associate, in our ⏰Off the Clock⏰ series. Learn about Erica's favorite aspect of her role, her creative outlets, and her latest hobby. #WeAreFlagship    🔍 Explore more spotlights on Flagship pioneers: https://bit.ly/4gdEZ0i    💼 Interested in joining the Flagship team? View our open roles: https://lnkd.in/dhM6gY6

#FlagshipFounded Indigo announces Microsoft’s commitment to purchase 60,000 soil carbon credits from the company’s fourth and largest carbon crop.

Catch Avak Kahvejian, Flagship General Partner, at the WBUR festival discussing the future of innovation in Massachusetts, including what’s ahead for biotech and life science companies. For more details: https://lnkd.in/disqMZcY

We’re excited to present new SER-155 Phase 1b exploratory biomarker data at #ASCO25. If you’re attending, we welcome you to stop by our poster and learn more! New data will build on our previous findings, focusing on the potential of SER-155 to promote immune reconstitution following allo-HSCT through the modulation of homeostatic cytokines and peripheral T-cell expansion. We’ll also share the poster on our website following the conference. Read more in today’s release: https://lnkd.in/eQauTzGZ

Learn more about #FlagshipFounded Sail Biomedicines in this Advancing RNA Q&A with Kerry Benenato and Rajesh Ramaswamy. ⬇️

Understanding the surface chemistry of lipid nanoparticles is essential to engineering RNA-based medicines with precision. In a collaborative study led by the University of Nottingham, Sail Biomedicines, Massachusetts Institute of Technology (MIT), and the UK’s National Physical Laboratory (NPL), scientists used Cryo-OrbiSIMS to map the structure and composition of LNPs like never before. Sail’s Chief Platform Officer Kerry Benenato said, “This technology paves the way for LNP-based therapeutics with tunable properties, including biodistribution—ultimately expanding the potential of RNA-based medicines.” Read the press release for more on this breakthrough: https://lnkd.in/eBFHRck9 #eRNA #RNA #endlessRNA #programmablemedicines #drugdelivery #tLNP #RNAdelivery #LipidNanoparticles

As the commencement speaker for the Worcester Polytechnic Institute graduate school class of 2025 last week, I was honored to be joined by President Grace W. and student representative Shelley Joshi. Interestingly, all three of us were born outside of the United States. As I told the graduates, being an immigrant has shaped my entire life and career. I arrived in Canada from Lebanon when I was 13, having never experienced snow and preferring Armenian folk dance to playing ice hockey. I didn’t move to the U.S. until I came for graduate school, like many of the graduate students I addressed on Thursday. Getting used to a new culture was uncomfortable—but it gave me an advantage that I’ve carried with me since. I often ask, “Why should we expect reasonable people doing reasonable things to deliver extraordinary results?” Being an immigrant gave me permission to be unreasonable. It taught me that it’s ok to be different. If you don’t know what’s expected, you’re not bound by what’s expected. I encouraged the graduates—whether born in Massachusetts or Malawi or Myanmar—to embrace an “immigrant mindset” and grow comfortable with the discomfort that so often drives innovation. Finally, I spoke about one of WPI’s most famous alums: Dr. Robert Goddard, the father of modern rocket science and the namesake of NASA Goddard Space Flight Center. He persevered through repeated disappointments to build the technology that eventually took humans to the moon. I encouraged the class of 2025 to do the same, channeling their energy into learning, iterating, and trying again rather than dwelling in disappointment when things don’t go as they had hoped. I also offered some thoughts about how graduates can apply these lessons to one of the emerging forces shaping our world: Artificial Intelligence. I encouraged them to make room for AI in their work, and to make use of it—opening the door to what I call “polyintelligence” and a new era of scientific discovery. For more on my thoughts on the synthesis of human, machine, and nature’s intelligence: https://lnkd.in/eVRdZ6Nk You can watch the full speech here: https://lnkd.in/eu7P66vB

This deal unites Thermo Fisher’s developmental and cGMP services, commercial manufacturing capabilities and global capacity with Mirai’s innovative technology platform for optimizing the design, delivery and development of novel nucleic acid therapeutics. Our own Michael Laska will lead the collaboration, which enhances Mirai’s end-to-end platform capabilities available to its partners. https://lnkd.in/gH6Kv5Qw

#FlagshipFounded Tessera Therapeutics presents new preclinical data across its in vivo genetic medicine programs for alpha-1 antitrypsin deficiency (AATD), phenylketonuria (PKU), and sickle cell disease (SCD), as well as advances in in vivo T cell therapies at the American Society of Gene & Cell Therapy Annual Meeting. For more: https://lnkd.in/eTPq2f-j #ASGCT2025